Overview

The Gene Technology Act 2000, enacted by the Parliament of Australia, is designed to regulate the use of gene technology in order to protect human health and the environment. The Act establishes a comprehensive framework for the assessment and regulation of genetically modified organisms (GMOs), including the assessment of risks and the implementation of risk management measures. The Act was introduced to address the need for a robust regulatory system to manage the potential risks associated with the use of gene technology, ensuring that any potential adverse effects on human health and the environment are identified and appropriately managed. The Office of the Gene Technology Regulator, as part of the Australian Government Department of Health, is responsible for administering the Act and ensuring compliance with its provisions. The policy objective of the Act is to facilitate the safe development and use of gene technology while protecting public health and the environment from any potential risks.

Scope and Application

The scope of C2014G01060 encompasses the regulation of genetically modified (GM) wheat and barley field trials under Australia's gene technology regulatory system. This Act applies to entities seeking to conduct such trials, specifically in this instance, The University of Adelaide, which has submitted Licence Application DIR 128 for assessment by the Gene Technology Regulator. The focus is on the limited and controlled release of GM wheat and barley engineered for abiotic stress tolerance or micronutrient uptake, intended solely for research purposes and not for human food or animal feed. Geographically, the Act pertains to trials proposed to be conducted within the states of South Australia and Western Australia, with a maximum area of 2.5 hectares per year across five trial sites. The Act extends its regulatory reach through the preparation of a consultation Risk Assessment and Risk Management Plan (RARMP) and draft licence conditions that govern the parameters of the trial to ensure minimal risk to human health, safety, and the environment. The Regulator’s invitation for submissions underscores the collaborative approach in finalising the RARMP, which will underpin the decision-making process regarding the issuance of the licence.

Key Provisions

The primary operative sections of the legislation (Gazette C2014G01060) concern the assessment and proposed trial of genetically modified (GM) wheat and barley by The University of Adelaide. Section 1 outlines the purpose of the trial, which is to assess the yield potential of genetically modified wheat and barley for abiotic stress tolerance or micronutrient uptake. Section 2 provides the timeframe for the trial, set between August 2014 and December 2019, and details the proposed trial sites in South Australia and Western Australia, with a collective maximum area of 2.5 hectares per year. Section 3 specifies that the GM wheat and barley will not be used in human food or animal feed. Section 4 discusses the consultation process and invites submissions to finalise the Risk Assessment and Risk Management Plan (RARMP), which assesses the risks posed by the GM plants. The obligations and requirements imposed by the Act primarily concern the assessment and management of risks associated with the proposed trial. The Gene Technology Regulator is tasked with assessing the Licence Application DIR 128 and preparing a RARMP to determine whether the proposed release poses a negligible risk to human health and safety or the environment. The University of Adelaide must comply with any draft licence conditions that the Regulator may impose to limit the size, locations, and duration of the release, as well as restrict the spread and persistence of the GMOs and the introduced genetic material. The Regulator must also ensure that the consultation process is thorough and considers all written submissions before making a decision on whether to issue the licence. The legislation includes provisions for offences, penalties, and civil/criminal consequences for breach, although specific details on these consequences are not provided in the text. It is likely that any breaches of the conditions of the licence or non-compliance with the requirements set out in the RARMP could result in legal action, including potential fines or other penalties as prescribed by relevant laws. The maximum penalties for such breaches would depend on the specific nature of the breach and the applicable legal framework governing gene technology in Australia. The text does not provide explicit details on the maximum penalties, but it is reasonable to assume that they would be in line with other regulatory frameworks governing gene technology and environmental protection.